Cargando…
Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia
Palliative care in acute myeloid leukaemia (AML) is inadequate. For elderly patients, unfit for intensive chemotherapy, median survival is 2–3 months. As such, there is urgent demand for low-toxic palliative alternatives. We have repositioned two commonly administered anti-leukaemia drugs, valproic...
Autores principales: | Leitch, Calum, Osdal, Tereza, Andresen, Vibeke, Molland, Maren, Kristiansen, Silje, Nguyen, Xuan Nhi, Bruserud, Øystein, Gjertsen, Bjørn Tore, McCormack, Emmet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884979/ https://www.ncbi.nlm.nih.gov/pubmed/26812881 http://dx.doi.org/10.18632/oncotarget.6991 |
Ejemplares similares
-
Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2019) -
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
por: Fredly, Hanne, et al.
Publicado: (2013) -
p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy
por: Haaland, Ingvild, et al.
Publicado: (2021) -
Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid
por: Forthun, Rakel Brendsdal, et al.
Publicado: (2012) -
Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML)
por: Omsland, Maria, et al.
Publicado: (2016)